Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna has dosed the first subject in what appears to be the first human trial of a Covid-19 booster vaccine designed to target a specific variant of the virus.

Moderna Doses First Subject in Covid-19 Booster Vaccine Trial

Moderna Inc. said late Wednesday that it vaccinated the first 60 people participating in a study meant to evaluate COVID-19 vaccine-booster candidates. That was out of "an abundance of caution" as previously published data has shown that its vaccine being currently administrated around the world has worked against all variants tested, including the U.K. and the South Africa strains, the company said.

Moderna vaccinates first people in study to test vaccine-booster candidates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dr. Elizabeth Nabel rejoins Moderna's Board of Directors.

Dr. Elizabeth Nabel Rejoins Moderna's Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces first participants dosed in study evaluating COVID-19 booster vaccine candidates.

Moderna Announces First Participants Dosed in Study Evaluating COVID-19 Booster Vaccine Candidates

Deere & Company

Johnson & Johnson

Healthpeak Properties

PepsiCo

Pfizer

Starbucks

AT&T

Verizon

WestRock

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Despite the COVID-19 pandemic, dividend income continues to grow, due primarily to additional investment and reinvestment. November through February 2021 proved to be pivotal moments for dividend investors, due to massive dividend increases.

Dividend Stock Purchase: Lanny's February 2021 Summary

But 2022 is likely to be the year that defines the company.

Moderna Looks for a Breakout in 2021

The stock is down big, but the company is coming off of an improved fourth quarter.

Should You Buy Moderna in March?

Hint: It's a company that's a lot bigger and that's been around a lot longer than Moderna.

Meet Moderna's Surprising New COVID Vaccine Partner

BioNTech SE

A year ago, a handful of vaccine stocks emerged out of relative obscurity as a deadly pandemic began claiming the lives of millions. But these stocks don't intend to stop at Covid-19.

The Pandemic Proved Their Worth — What's Next For Moderna, BioNTech?

Align Technology

Cadence Design Systems

KLA-Tencor

NVIDIA

We highlighted five stocks from the ETF that were hit badly in the tech rout but might reverse the trend, given their solid Zacks Rank #1 (Strong Buy) or 2 (Buy) and positive earnings estimate revisions in a month.

5 Beaten-Down Stocks of Nasdaq ETF With Upside Potential

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna named Fast Company's Most Innovative Company for 2021.

Moderna Named Fast Company's Most Innovative Company for 2021

IBM and Moderna (MRNA) team up to explore utility of hybrid cloud and blockchain technology to enhance COVID-19 vaccine management and stem the spread of the contagion.

IBM & Moderna Partner to Augment COVID-19 Vaccine Management

Baxter

Baxter International Inc (NYSE: BAX) has agreed to provide manufacturing services for Moderna Inc's (NASDAQ: MRNA) COVID-19 Vaccine. The agreement includes fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 Vaccine in 2021.

Baxter To Offer Fill/Finish Services To Moderna's COVID-19 Vaccine In US

Baxter International Inc. announced Monday an agreement with Moderna Inc. , in which Baxter will provide sterile manufacturing services and supply packaging for 60 million to 90 million doses of Moderna's COVID-19 vaccine. Baxter's stock is little changed in premarket trading, while Moderna shares fell 1.4%.

Baxter to provide sterile manufacturing, packaging for Moderna's COVID-19 vaccine

DEERFIELD, Ill., AND CAMBRIDGE, Mass..--(BUSINESS WIRE)--Baxter BioPharma Solutions and Moderna announce agreement for fill/finish manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Baxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Moderna Inc (NASDAQ: MRNA) has agreed to supply the Philippines government with 13 million doses of its COVID-19 vaccine. Deliveries are set to begin in mid-2021.

Philippines, Moderna Reach 13M Vaccine Doses Supply Pact

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shannon Thyme Klinger joins Moderna as Chief Legal Officer and Corporate Secretary.

Shannon Thyme Klinger Joins Moderna as Chief Legal Officer and Corporate Secretary

The competitive landscape is flattening out.

Moderna and Pfizer's Second-Gen Coronavirus Vaccines: What Investors Need to Know

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces supply agreement to provide 13 million doses of COVID-19 Vaccine Moderna to the Philippines.

Moderna Announces Supply Agreement to Provide 13 Million Doses of COVID-19 Vaccine Moderna to the Philippines

How Worried Should Investors Be About the South African Coronavirus Variant?

Today, the risk is different for each vaccine stock.

Is Short-Selling a Risk for Moderna?

2 Green Flags for Moderna in 2021 and 1 Yellow Flag

AstraZeneca

CureVac B.V

Novavax

Sinovac Biotech

The companies in line for the biggest gains – and the shareholders who have already made fortunes

From Pfizer to Moderna: who's making billions from Covid-19 vaccines?

Several bits of news were buffeting the stock in various directions.

Why Moderna Was a Roller Coaster Today

Moderna and IBM are joining forces to collaborate on strengthening and improving COVID-19 vaccination management, the companies announced on Thursday (March 4). The collaboration will use IBM blockchain and artificial intelligence (AI) to improve the vaccine supply chain and expand data sharing.

News for Moderna Stock (MRNA)